보고서 요약(국문)

시장 개요
전 세계 불응성 다발성 골수종 시장은 2022년 24억 달러 규모에 도달했으며, 2030년까지 34억 달러에 이를 것으로 예상되어 높은 성장세를 보일 전망입니다. 전 세계 불응성 다발성 골수종 시장은 2023년부터 2030년까지 연평균 4.7%의 성장률을 기록할 것으로 예상됩니다. 기술 발전과 신약 개발을 위한 임상 시험 증가가 불응성 다발성 골수종 시장 수요 증가를 견인하고 있습니다.
다발성 골수종은 여전히 완치 불가능한 질환이지만, 카르필조밉, 보르테조밉, 익사조밉과 같은 프로테아좀 억제제(PI)와 레날리도마이드, 탈리도마이드, 포말리도마이드와 같은 면역 조절제 개발 덕분에 지난 15년간 의료 서비스가 크게 개선되었습니다.

난치성 다발성 골수종 시장은 프로테아좀 억제제, 면역조절제, 항-CD38 단클론 항체, 키메라 항원 수용체(CAR-T) 치료제 등을 포함한 다양한 약물 유형을 포괄하며, 이는 난치성 다발성 골수종 시장 점유율 증가에 기여했습니다.
전 세계 난치성 다발성 골수종 시장은 연구 개발 증가와 각국의 신약 승인 예정 등 여러 요인으로 인해 성장하고 있으며, 이러한 요인들은 난치성 다발성 골수종 시장 성장에 긍정적인 전망을 제시하고 있습니다.

시장 동향
신약 출시 증가가 난치성 다발성 골수종 시장 성장을 견인합니다.

지난 몇 년간 다발성 골수종 연구를 위한 신약 출시가 크게 증가했습니다. 전 세계적으로 난치성 다발성 골수종 치료법 개선 및 질병 연구를 위한 수많은 연구가 진행되고 있습니다. 최근 연구에 따르면 다발성 골수종(MM) 환자의 생존율을 높이기 위해서는 장기적이고 지속적인 치료가 필요합니다.

예를 들어, 2022년 12월 8일, 프레제니우스 카비(Fresenius Kabi)는 폴로틴(Folotyn)의 제네릭 대체제인 프랄라트렉세이트 주사제를 재발성 또는 내성 말초 T세포 림프종 치료제로 출시했습니다. 미국 의료계에서 가장 광범위한 주사형 항암제 라인업에 새롭게 추가된 프레제니우스 카비 프랄라트렉세이트 주사제는 현재 미국에서 시판 중입니다.
재발성 또는 불응성 말초 T세포 림프종을 앓는 성인 환자는 프레제니우스 카비 프랄라트렉세이트 주사제를 통해 제네릭 치료 옵션을 이용할 수 있습니다. 프레제니우스 카비 프랄라트렉세이트 주사제는 40mg/2mL와 20mg/1mL의 두 가지 단회 투여용 바이알 제형으로 제공됩니다.
규제 승인 증가와 파이프라인 확대는 제조업체에 수익성 높은 기회를 창출하고 있습니다.
수많은 연구원과 연구 펠로우들의 임상 연구 및 기초 과학 연구에 대한 기여는 새로운 치료법 개발을 가속화하고 질병의 기원과 경과에 대한 이해를 크게 향상시켰습니다. 여러 임상 시험이 진행 중이며, 긍정적인 결과가 나오고 있습니다.
예를 들어, 2023년 5월 16일, 로슈 그룹의 자회사인 제넨텍은 재발성 다발성 경화증(RMS) 환자를 대상으로 경구용 페네브루티닙을 시험하는 FENopta 연구의 2상 시험에서 긍정적인 결과를 발표했습니다.
이 연구는 경구용 페네브루티닙이 위약 대비 뇌의 MS 질병 활동 자기공명영상(MRI) 지표를 유의미하게 감소시키는 것을 보여주었으며, 이는 페네브루티닙이 1차 및 2차 목표를 달성했음을 입증합니다. 또한, 전임상 연구에서는 페네브루티닙의 효능과 우수한 선택성이 확인되었으며, 현재 MS 치료를 위해 3상 임상 시험 중인 유일한 가역적 억제제입니다.

약물 관련 부작용은 시장 성장을 저해할 것입니다.
그러나 치료 부담은 여전히 다발성 경화증 치료 기간을 단축시키므로, 환자의 삶의 질에 미치는 치료의 부정적인 영향을 줄이는 방법을 개발하는 것이 중요합니다. 혈소판 감소증 및 호중구 감소증과 같은 혈액학적 부작용, 메스꺼움, 구토 및 설사와 같은 위장관 부작용, 심부정맥 혈전증 또는 폐색전증과 같은 정맥 혈전성 부작용, 그리고 발진 및 말초 신경병증과 같은 부작용은 이러한 치료와 관련된 가장 빈번하게 보고되는 문제입니다.
자가 치료 시 경구 약물을 복용하는 환자는 가능한 한 빨리, 가급적 치료가 어려워지기 전에 증상을 보고해야 합니다. 효과적이고 지속적이며 실용적인 다발성 골수종 치료는 이러한 치료 관련 부작용을 적절히 관리하고, 식이요법과 약물 병용을 모니터링하며, 환자의 자비 부담 비용을 지원하는 데 달려 있습니다.
COVID-19 영향 분석
COVID-19 유행병과 전 세계적인 봉쇄 조치는 모든 산업 분야의 기업의 재정 건전성에 영향을 미쳤습니다. 그 결과, 미국 식품의약국(FDA)은 코로나19 보건 비상사태에 대한 지침을 발표했는데, 이 지침에는 스폰서와 연구자를 지원하고, 임상시험 참가자의 안전을 보장하며, 우수 임상시험 관리기준(GCP)을 준수하고, 임상시험의 무결성에 대한 위험을 줄이기 위한 일반적인 고려 사항이 포함되어 있습니다.
러시아-우크라이나 전쟁 영향 분석
러시아-우크라이나 분쟁은 해당 지역의 주요 시장 참여자 수가 적기 때문에 전 세계 난치성 다발성 골수종 시장에 미치는 영향이 미미할 것으로 예상됩니다. 그러나 원자재의 수출입은 예측 기간 동안 전 세계 난치성 다발성 골수종 시장 성장에 거의 영향을 미치지 않을 것으로 예상됩니다.
세분화 분석
전 세계 난치성 다발성 골수종 시장은 약물 유형, 투여 경로, 제품 유형, 최종 사용자 및 지역별로 세분화됩니다.
약물 유형 부문 중 경구 투여 약물이 시장 점유율의 76.3%를 차지합니다. 새로운 치료제의 등장으로
새로운 치료제의 시대에 접어들면서, 경구용 다발성 골수종(MM) 치료 요법은 흔히 면역 조절제와 코르티코스테로이드(가장 흔하게는 덱사메타손) 병용 요법, 또는 면역 조절제와 코르티코스테로이드 또는 알킬화제(예: 시클로포스파미드와 덱사메타손[Cd] 또는 멜팔란과 프레드니손[MP]) 병용 요법으로 구성됩니다.
표준 치료법인 레날리도마이드-덱사메타손(Rd) 요법과 비교했을 때, 레날리도마이드-시클로포스파미드-프레드니손 요법 및 레날리도마이드와 MP를 병용한 삼중 요법(MPR)은 특별히 효과적이지는 않은 것으로 알려져 있습니다. 그러나 보르테조밉, 카르필조밉, 익사조밉을 Rd 요법과 병용했을 때 나타난 것처럼, 면역 조절제 또는 프로테아제 억제제(PI)를 포함하는 삼중 요법이 신속하고 강력한 반응을 유도하고 무진행 생존 기간을 연장하는 데 특히 효과적이라는 연구 결과가 있습니다.

최근 미국 식품의약국(FDA)의 승인을 받은 익사조밉과 리도파민(Rd) 병용 요법은 이전에 최소 한 번 이상의 치료를 받은 다발성 골수종 환자에게 사용할 수 있는 경구용 면역 조절제 및 프로테아제 억제제(PI) 함유 3제 요법입니다. 포말리도마이드와 덱사메타손 또는 카듐(Cd) 병용 요법 또한 재발성 질환 환자에게 효과적인 경구 요법입니다.
지역 분석
북미는 주요 업체들의 강력한 입지와 기술 발전으로 인해 시장 점유율의 약 42.7%를 차지했습니다.
북미 지역의 난치성 다발성 골수종 치료제 수요 증가로 인해 제조업체들은 이 지역에서 사업을 확장할 기회를 얻고 있습니다. 북미에는 많은 제조업체와 공급업체가 있으며, 빠른 경제 성장으로 인해 난치성 다발성 골수종 치료제의 생산이 증가하고 있으며, 이는 수요 증가로 이어지고 있습니다.
북미에는 많은 제조업체와 공급업체가 있습니다. 이 지역의 빠른 경제 성장으로 인해 생산이 증가했으며, 이는 다발성 골수종 치료에 대한 수요를 충족시키고 있습니다.

새로운 치료제나 기술이 등장함에 따라 시장은 성장할 것입니다. 기술 발전, 정부 승인, 신제품 출시 등이 성장에 기여하고 있습니다. 사람들의 새로운 기술과 다발성 골수종에 대한 인식이 높아짐에 따라 이 지역의 시장이 확대되고 있습니다. 이러한 요인들은 북미 시장의 지배력을 보여줍니다.
경쟁 환경
난치성 다발성 골수종 시장의 주요 글로벌 기업으로는 Bristol Myers Squibb, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Janssen Global Services, LLC, Fresenius Kabi, Gilead Sciences, Inc., GSK plc., Takeda Pharmaceutical Company Limited, Novartis AG, Genentech, Inc. 등이 있습니다.
보고서 구매 이유

• 약물 유형, 투여 경로, 제품 유형, 최종 사용자 및 지역별 글로벌 난치성 다발성 골수종 시장 세분화를 시각화하고 주요 상업적 자산과 기업을 파악하기 위해

• 트렌드 및 공동 개발 분석을 통해 사업 기회를 식별하기 위해

• 모든 세그먼트를 포함한 난치성 다발성 골수종 시장 수준의 다양한 데이터가 담긴 엑셀 데이터 시트.

• 심층적인 질적 인터뷰와 연구를 바탕으로 한 종합적인 분석이 담긴 PDF 보고서.

• 주요 업체들의 핵심 제품을 모두 포함하는 제품 맵핑 엑셀 파일 제공.
글로벌 난치성 다발성 골수종 시장 보고서는 약 53개의 표, 54개의 그림, 195페이지 분량으로 구성됩니다.
주요 고객 (2023년 기준)
• 제조업체/구매자
• 산업 투자자/투자 은행가
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Market Overview
The Global Refractory Multiple Myeloma Market reached US$ 2.4 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 3.4 billion by 2030. The Global Refractory Multiple Myeloma Market is expected to exhibit a CAGR of 4.7% during the forecast period 2023-2030. The increasing technological advancements and the growing clinical trials for novel drugs drive demand for refractory multiple myeloma market trends.
Even though MM is still incurable, medical care has improved over the past 15 years thanks to the development of proteasome inhibitors (PIs) such as carfilzomib, bortezomib, and ixazomib as well as immunomodulatory medications like lenalidomide, thalidomide, and pomalidomide.
The refractory multiple myeloma market scope comprises drug type as proteasome inhibitors, immunomodulators, anti-CD38 monoclonal antibodies, chimeric antigen receptor (CAR-T) therapy and others, which has increased the refractory multiple myeloma market share.
The global market for refractory multiple myeloma is expanding due to factors including increasing research and development and their upcoming novel product approvals across countries are also creating a positive outlook for the refractory multiple myeloma market growth.
Market Dynamics
The Rising Novel Product Launches Drive the Growth of the Refractory Multiple Myeloma Market.
Over the past few years, there has been a considerable increase in the number of novel product launches for multiple myeloma research. Numerous studies are being carried out globally to improve refractory multiple myeloma treatment to study the illness. According to recent research, multiple myeloma (MM) patients need long-term, ongoing treatment to increase survival.
For instance, on December 8, 2022, as a generic alternative to Folotyn, Pralatrexate Injection has been made available by the healthcare company Fresenius Kabi for the treatment of peripheral T-cell lymphoma that has returned or become resistant. The newest addition to the greatest array of injectable oncology medications in American healthcare is Fresenius Kabi Pralatrexate Injection, which is currently available in the country.
Adult patients with recurrent or refractory peripheral T-cell lymphoma have a generic therapeutic option with Fresenius Kabi Pralatrexate Injection. There are two single-dose vial presentations of Fresenius Kabi Pralatrexate Injection: 40 mg/2 mL and 20 mg/1 mL.
Rising Regulatory Approval and Pipeline Creates Lucrative Opportunities for Manufacturers.
Contributions to clinical research and fundamental science research from a number of researchers or fellows have accelerated the development of novel treatments and significantly improved the understanding of the origins and course of disorders. Several clinical trials are being conducted, resulting in positive outcomes.
For instance, on May 16, 2023, Positive findings from the second phase of the FENopta study testing experimental oral fenebrutinib in people having relapsing types of multiple sclerosis (RMS) were released by Genentech, a subsidiary of the Roche Group.
The research demonstrated that oral fenebrutinib significantly decreased magnetic resonance imaging (MRI) markers for MS disease activity in the brain when compared to placebo, demonstrating that it accomplished its primary and secondary goals. In addition, pre-clinical studies showed the potency and good selectivity of fenebrutinib, the one and only reversible inhibitor now being tested in Phase III studies for MS.
Side Effects Linked with Drugs will Hamper the Growth of the Market.
However, the treatment burden still shortens the duration of MM therapy; as a result, it is crucial to develop ways to reduce the negative effects of treatment on the patient's quality of life. Hematologic side effects like thrombocytopenia and neutropenia, gastrointestinal side effects like nausea, vomiting, and diarrhea, venous thrombotic side effects like deep-vein thrombosis or pulmonary embolism, and side effects like rash and peripheral neuropathy are the most frequently reported problems associated with these treatments.
Patients taking oral medicines at home should report symptoms as soon as possible, preferably before they become challenging to treat. Effective, long-lasting, and practical MM therapy depends on properly managing such treatment-related adverse effects, monitoring both dietary and drug combinations, and assisting with out-of-pocket expenses for patients.
COVID-19 Impact Analysis
The COVID-19 epidemic and the worldwide lockdown have affected the financial health of businesses in all industries. As a result, the U.S. Food and Drug Administration (FDA) released guidelines for the COVID-19 health emergency that include general considerations to assist sponsors and researchers, ensure trial participants' safety, follow good clinical practice (GCP), and reduce risks to trial integrity.
Russia-Ukraine War Impact Analysis
The Russia-Ukraine conflict is estimated to have a low impact on the global refractory multiple myeloma market, owing to the low number of key market players in this region. However, the impact of the import and export of raw materials is expected to have little influence over the global refractory multiple myeloma market growth over the forecast period.
Segment Analysis
The Global Refractory Multiple Myeloma Market is segmented based on drug type, route of administration, product type, end user and region.
Oral from Drug Type Segment Accounts for 76.3% of the Market Share. Owing to Rising Availability
In the era of new therapeutics, oral MM regimens often consist of an immunomodulatory medication plus a corticosteroid (most commonly dexamethasone) or an immunomodulatory medication plus a corticosteroid or an alkylating agent (like cyclophosphamide and dexamethasone [Cd] or melphalan and prednisone [MP]).
Although compared to the standard of treatment lenalidomide-dexamethasone (Rd), lenalidomide cyclophosphamide-prednisone and the triplet regimens lenalidomide with MP (MPR) be not particularly beneficial. As seen with bortezomib, carfilzomib, and ixazomib when combined with Rd, studies have indicated that an immunomodulatory drug- or PI-containing triplet therapy is particularly effective at eliciting rapid, profound responses and enhancing progression-free survival.
An alloral immunomodulatory medication and PI-containing triplet regimen is accessible with the recent US Food and Medication Administration (FDA) clearance of ixazomib when combined with Rd for individuals with MM who have undergone at least one prior therapy. Pomalidomide with dexamethasone or Cd is another active all-oral regimen for individuals with relapsed illness.
Geographical Analysis
North America Accounted for Approximately 42.7% of the Market Share, Owing to the Strong Presence of Major Players and Rising Technological Advancements.
Manufacturers have chances to expand their operations in this region because of the rising demand for refractory multiple myeloma for advancements in North America. The area has many producers and suppliers, and its rapid economic development has raised industrial production of refractory multiple myeloma, increasing demand.
There are many manufacturers and suppliers in North America. As a result of the region's rapid economic growth, industrial production has expanded, feeding the desire for the treatment of multiple myeloma.
The market will grow as new items or technology for treatment emerge. Rising technological developments, governmental approvals, and introducing of new products contribute to growth. People are becoming more aware of novel technologies and myelomas, expanding the market in this region. These factors show the dominance of North America.
Competitive Landscape
The major global players in the refractory multiple myeloma market include Bristol Myers Squibb, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Janssen Global Services, LLC, Fresenius Kabi, Gilead Sciences, Inc., GSK plc., Takeda Pharmaceutical Company Limited, Novartis AG and Genentech, Inc. among others.
Why Purchase the Report?
• To visualize the Global Refractory Multiple Myeloma Market segmentation based on drug type, route of administration, product type, end user and region, and understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous refractory multiple myeloma market-level data points with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.
The Global Refractory Multiple Myeloma Market Report Would Provide Approximately 53 Tables, 54 Figures And 195 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Drug Type
3.2. Snippet by Route of Administration
3.3. Snippet by Product Type
3.4. Snippet by End User
3.5. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. The Rising Novel Product Launches
4.1.1.2. Increasing Incidence of Multiple Myeloma
4.1.2. Restraints
4.1.2.1. Side Effects Associated with the Treatment
4.1.3. Opportunity
4.1.3.1. Rising Regulatory Approval and Pipeline
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID-19
6.1.2. Scenario During COVID-19
6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Drug Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
7.1.2. Market Attractiveness Index, By Drug Type
7.2. Proteosome Inhibitor *
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Immunomodulators
7.4. Anti-CD38 Monoclonal Antibody
7.5. Others
8. By Route of Administration
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
8.1.2. Market Attractiveness Index, By Route of Administration
8.2. Oral *
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Parenteral
9. By Product Type
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
9.1.2. Market Attractiveness Index, By Product Type
9.2. Tablet *
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Capsule
9.4. Solution
9.5. Suspension
10. By End User
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.1.2. Market Attractiveness Index, By End User
10.2. Hospitals *
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Surgical Centres/ Clinics
10.4. Others
11. By Region
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.7.1. The U.S.
11.2.7.2. Canada
11.2.7.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.7.1. Germany
11.3.7.2. The U.K.
11.3.7.3. France
11.3.7.4. Spain
11.3.7.5. Italy
11.3.7.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.7.1. Brazil
11.4.7.2. Argentina
11.4.7.3. Rest of South America
11.5. Asia-Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.7.1. China
11.5.7.2. India
11.5.7.3. Japan
Australia
11.5.7.4. Rest of Asia-Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
12. Competitive Landscape
12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis
13. Company Profiles
13.1. Bristol Myers Squibb *
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Financial Overview
13.1.4. Key Developments
13.2. Teva Pharmaceutical Industries Ltd.
13.3. Pfizer Inc.
13.4. Janssen Global Services, LLC
13.5. Gilead Sciences, Inc.
13.6. Fresenius Kabi
13.7. GSK plc.
13.8. Novartis AG
13.9. Takeda Pharmaceutical Company Limited
13.10. Genentech, Inc.
LIST NOT EXHAUSTIVE
14. Appendix
14.1. About Us and Services
14.2. Contact Us

언급된 주요 기업들

Bristol Myers Squibb, 4.	Key Developments, Teva Pharmaceutical Industries Ltd., Pfizer Inc., Janssen Global Services, LLC, Gilead Sciences, Inc., Fresenius Kabi, GSK plc., Novartis AG, Takeda Pharmaceutical Company Limited, Genentech, Inc.

표 목록 (Tables)

List of Tables Table 1 Global Refractory Multiple Myeloma Market Value, By Drug Type, 2022, 2026 & 2030 (US$ Billion)

Table 2 Global Refractory Multiple Myeloma Market Value, By Route of Administration, 2022, 2026 & 2030 (US$ Billion)

Table 3 Global Refractory Multiple Myeloma Market Value, By Product Type, 2022, 2026 & 2030 (US$ Billion)

Table 4 Global Refractory Multiple Myeloma Market Value, By End User, 2022, 2026 & 2030 (US$ Billion)

Table 5 Global Refractory Multiple Myeloma Market Value, By Region, 2022, 2026 & 2030 (US$ Billion)

Table 6 Global Refractory Multiple Myeloma Market Value, By Drug Type, 2022, 2026 & 2030 (US$ Billion)

Table 7 Global Refractory Multiple Myeloma Market Value, By Drug Type, 2021-2030 (US$ Billion)

Table 8 Global Refractory Multiple Myeloma Market Value, By Route of Administration, 2022, 2026 & 2030 (US$ Billion)

Table 9 Global Refractory Multiple Myeloma Market Value, By Route of Administration, 2021-2030 (US$ Billion)

Table 10 Global Refractory Multiple Myeloma Market Value, By Product Type, 2022, 2026 & 2030 (US$ Billion)

Table 11 Global Refractory Multiple Myeloma Market Value, By Product Type, 2021-2030 (US$ Billion)

Table 12 Global Refractory Multiple Myeloma Market Value, By End User, 2022, 2026 & 2030 (US$ Billion)

Table 13 Global Refractory Multiple Myeloma Market Value, By End User, 2021-2030 (US$ Billion)

Table 14 Global Refractory Multiple Myeloma Market Value, By Region, 2022, 2026 & 2030 (US$ Billion)

Table 15 Global Refractory Multiple Myeloma Market Value, By Region, 2021-2030 (US$ Billion)

Table 16 North America Refractory Multiple Myeloma Market Value, By Drug Type, 2021-2030 (US$ Billion)

Table 17 North America Refractory Multiple Myeloma Market Value, By Route of Administration, 2021-2030 (US$ Billion)

Table 18 North America Refractory Multiple Myeloma Market Value, By Product Type, 2021-2030 (US$ Billion)

Table 19 North America Refractory Multiple Myeloma Market Value, By End User, 2021-2030 (US$ Billion)

Table 20 North America Refractory Multiple Myeloma Market Value, By Country, 2021-2030 (US$ Billion)

Table 21 South America Refractory Multiple Myeloma Market Value, By Drug Type, 2021-2030 (US$ Billion)

Table 22 South America Refractory Multiple Myeloma Market Value, By Route of Administration, 2021-2030 (US$ Billion)

Table 23 South America Refractory Multiple Myeloma Market Value, By Product Type, 2021-2030 (US$ Billion)

Table 24 South America Refractory Multiple Myeloma Market Value, By End User, 2021-2030 (US$ Billion)

Table 25 South America Refractory Multiple Myeloma Market Value, By Country, 2021-2030 (US$ Billion)

Table 26 Europe Refractory Multiple Myeloma Market Value, By Drug Type, 2021-2030 (US$ Billion)

Table 27 Europe Refractory Multiple Myeloma Market Value, By Route of Administration, 2021-2030 (US$ Billion)

Table 28 Europe Refractory Multiple Myeloma Market Value, By Product Type, 2021-2030 (US$ Billion)

Table 29 Europe Refractory Multiple Myeloma Market Value, By End User, 2021-2030 (US$ Billion)

Table 30 Europe Refractory Multiple Myeloma Market Value, By Country, 2021-2030 (US$ Billion)

Table 31 Asia-Pacific Refractory Multiple Myeloma Market Value, By Drug Type, 2021-2030 (US$ Billion)

Table 32 Asia-Pacific Refractory Multiple Myeloma Market Value, By Route of Administration, 2021-2030 (US$ Billion)

Table 33 Asia-Pacific Refractory Multiple Myeloma Market Value, By Product Type, 2021-2030 (US$ Billion)

Table 34 Asia-Pacific Refractory Multiple Myeloma Market Value, By End User, 2021-2030 (US$ Billion)

Table 35 Asia-Pacific Refractory Multiple Myeloma Market Value, By Country, 2021-2030 (US$ Billion)

Table 36 Middle East & Africa Refractory Multiple Myeloma Market Value, By Drug Type, 2021-2030 (US$ Billion)

Table 37 Middle East & Africa Refractory Multiple Myeloma Market Value, By Route of Administration, 2021-2030 (US$ Billion)

Table 38 Middle East & Africa Refractory Multiple Myeloma Market Value, By Product Type, 2021-2030 (US$ Billion)

Table 39 Middle East & Africa Refractory Multiple Myeloma Market Value, By End User, 2021-2030 (US$ Billion)

Table 40 Bristol Myers Squibb : Overview

Table 41 Bristol Myers Squibb : Product Portfolio

Table 42 Bristol Myers Squibb : Key Developments

Table 43 Teva Pharmaceutical Industries Ltd.: Overview

Table 44 Teva Pharmaceutical Industries Ltd.: Product Portfolio

Table 45 Teva Pharmaceutical Industries Ltd.: Key Developments

Table 46 Pfizer Inc.: Overview

Table 47 Pfizer Inc.: Product Portfolio

Table 48 Pfizer Inc.: Key Developments

Table 49 Janssen Global Services, LLC : Overview

Table 50 Janssen Global Services, LLC : Product Portfolio

Table 51 Janssen Global Services, LLC : Key Developments

Table 52 Gilead Sciences, Inc.: Overview

Table 53 Gilead Sciences, Inc.: Product Portfolio

Table 54 Gilead Sciences, Inc.: Key Developments

Table 55 Fresenius Kabi: Overview

Table 56 Fresenius Kabi: Product Portfolio

Table 57 Fresenius Kabi: Key Developments

Table 58 GSK plc.: Overview

Table 59 GSK plc.: Product Portfolio

Table 60 GSK plc.: Key Developments

Table 61 Novartis AG : Overview

Table 62 Novartis AG : Product Portfolio

Table 63 Novartis AG : Key Developments

Table 64 Takeda Pharmaceutical Company Limited: Overview

Table 65 Takeda Pharmaceutical Company Limited: Product Portfolio

Table 66 Takeda Pharmaceutical Company Limited: Key Developments

Table 67 Genentech, Inc.: Overview

Table 68 Genentech, Inc.: Product Portfolio

Table 69 Genentech, Inc.: Key Developments

그림 목록 (Figures)

List of Figures Figure 1 Global Refractory Multiple Myeloma Market Value, 2021-2030 (US$ Billion)

Figure 2 Global Refractory Multiple Myeloma Market Share, By Drug Type, 2022 & 2030 (%)

Figure 3 Global Refractory Multiple Myeloma Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 4 Global Refractory Multiple Myeloma Market Share, By Product Type, 2022 & 2030 (%)

Figure 5 Global Refractory Multiple Myeloma Market Share, By End User, 2022 & 2030 (%)

Figure 6 Global Refractory Multiple Myeloma Market Share, By Region, 2022 & 2030 (%)

Figure 7 Global Refractory Multiple Myeloma Market Y-o-Y Growth, By Drug Type, 2022-2030 (%)

Figure 8 Proteosome Inhibitor Refractory Multiple Myeloma Market Value, 2021-2030 (US$ Billion)

Figure 9 Immunomodulators Refractory Multiple Myeloma Market Value, 2021-2030 (US$ Billion)

Figure 10 Anti -CD38 Monoclonal Antibody Refractory Multiple Myeloma Market Value, 2021-2030 (US$ Billion)

Figure 11 Chimeric Antigen Receptor (CAR-T) therapy Refractory Multiple Myeloma Market Value, 2021-2030 (US$ Billion)

Figure 12 Others Refractory Multiple Myeloma Market Value, 2021-2030 (US$ Billion)

Figure 13 Global Refractory Multiple Myeloma Market Y-o-Y Growth, By Route of Administration, 2022-2030 (%)

Figure 14 Oral Route of Administration in Global Refractory Multiple Myeloma Market Value, 2021-2030 (US$ Billion)

Figure 15 Parenteral Route of Administration in Global Refractory Multiple Myeloma Market Value, 2021-2030 (US$ Billion)

Figure 16 Global Refractory Multiple Myeloma Market Y-o-Y Growth, By Product Type, 2022-2030 (%)

Figure 17 Tablet Product Type in Global Refractory Multiple Myeloma Market Value, 2021-2030 (US$ Billion)

Figure 18 Capsule Product Type in Global Refractory Multiple Myeloma Market Value, 2021-2030 (US$ Billion)

Figure 19 Solution Product Type in Global Refractory Multiple Myeloma Market Value, 2021-2030 (US$ Billion)

Figure 20 Suspension Product Type in Global Refractory Multiple Myeloma Market Value, 2021-2030 (US$ Billion)

Figure 21 Global Refractory Multiple Myeloma Market Y-o-Y Growth, By End User, 2022-2030 (%)

Figure 22 Hospitals End User in Global Refractory Multiple Myeloma Market Value, 2021-2030 (US$ Billion)

Figure 23 Surgical Centres/ Clinics End User in Global Refractory Multiple Myeloma Market Value, 2021-2030 (US$ Billion)

Figure 24 Others End User in Global Refractory Multiple Myeloma Market Value, 2021-2030 (US$ Billion)

Figure 25 Global Refractory Multiple Myeloma Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 26 North America Refractory Multiple Myeloma Market Value, 2021-2030 (US$ Billion)

Figure 27 Asia-Pacific Refractory Multiple Myeloma Market Value, 2021-2030 (US$ Billion)

Figure 28 Europe Refractory Multiple Myeloma Market Value, 2021-2030 (US$ Billion)

Figure 29 South America Refractory Multiple Myeloma Market Value, 2021-2030 (US$ Billion)

Figure 30 Middle East and Africa Refractory Multiple Myeloma Market Value, 2021-2030 (US$ Billion)

Figure 31 North America Refractory Multiple Myeloma Market Value, 2021-2030 (US$ Billion)

Figure 32 North America Refractory Multiple Myeloma Market Share, By Drug Type, 2022 & 2030 (%)

Figure 33 North America Refractory Multiple Myeloma Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 34 North America Refractory Multiple Myeloma Market Share, By Product Type, 2022 & 2030 (%)

Figure 35 North America Refractory Multiple Myeloma Market Share, By End User, 2022 & 2030 (%)

Figure 36 North America Refractory Multiple Myeloma Market Share, By Country, 2022 & 2030 (%)

Figure 37 South America Refractory Multiple Myeloma Market Value, 2021-2030 (US$ Billion)

Figure 38 South America Refractory Multiple Myeloma Market Share, By Drug Type, 2022 & 2030 (%)

Figure 39 South America Refractory Multiple Myeloma Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 40 South America Refractory Multiple Myeloma Market Share, By Product Type, 2022 & 2030 (%)

Figure 41 South America Refractory Multiple Myeloma Market Share, By End User, 2022 & 2030 (%)

Figure 42 South America Refractory Multiple Myeloma Market Share, By Country, 2022 & 2030 (%)

Figure 43 Europe Refractory Multiple Myeloma Market Value, 2021-2030 (US$ Billion)

Figure 44 Europe Refractory Multiple Myeloma Market Share, By Drug Type, 2022 & 2030 (%)

Figure 45 Europe Refractory Multiple Myeloma Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 46 Europe Refractory Multiple Myeloma Market Share, By Product Type, 2022 & 2030 (%)

Figure 47 Europe Refractory Multiple Myeloma Market Share, By End User, 2022 & 2030 (%)

Figure 48 Europe Refractory Multiple Myeloma Market Share, By Country, 2022 & 2030 (%)

Figure 49 Asia-Pacific Refractory Multiple Myeloma Market Value, 2021-2030 (US$ Billion)

Figure 50 Asia-Pacific Refractory Multiple Myeloma Market Share, By Drug Type, 2022 & 2030 (%)

Figure 51 Asia-Pacific Refractory Multiple Myeloma Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 52 Asia-Pacific Refractory Multiple Myeloma Market Share, By Product Type, 2022 & 2030 (%)

Figure 53 Asia-Pacific Refractory Multiple Myeloma Market Share, By End User, 2022 & 2030 (%)

Figure 54 Asia-Pacific Refractory Multiple Myeloma Market Share, By Country, 2022 & 2030 (%)

Figure 55 Middle East & Africa Refractory Multiple Myeloma Market Value, 2021-2030 (US$ Billion)

Figure 56 Middle East & Africa Refractory Multiple Myeloma Market Share, By Drug Type, 2022 & 2030 (%)

Figure 57 Middle East & Africa Refractory Multiple Myeloma Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 58 Middle East & Africa Refractory Multiple Myeloma Market Share, By Product Type, 2022 & 2030 (%)

Figure 59 Middle East & Africa Refractory Multiple Myeloma Market Share, By End User, 2022 & 2030 (%)

Figure 60 Bristol Myers Squibb : Financials

Figure 61 Teva Pharmaceutical Industries Ltd.: Financials

Figure 62 Pfizer Inc.: Financials

Figure 63 Janssen Global Services, LLC : Financials

Figure 64 Gilead Sciences, Inc.: Financials

Figure 65 Fresenius Kabi: Financials

Figure 66 GSK plc.: Financials

Figure 67 Novartis AG : Financials

Figure 68 Takeda Pharmaceutical Company Limited: Financials

Figure 69 Genentech, Inc.: Financials

세계 난치성 다발성 골수종 시장 – 2023-2030

Global Refractory Multiple Myeloma Market - 2023-2030